Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry

mAbs

Volumn 8, Issue 1, 2016, Pages 49-55

  Schaefer, Wolfgang ^a   Völger, Hans R ^a   Lorenz, Stefan ^a   Imhof Jung, Sabine ^a   Regula, Jörg T ^a   Klein, Christian ^b   Mølhøj, Michael ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b Roche Innovation Center Zurich   (Switzerland)

Author keywords

Bispecific antibody; Chain pairing; CrossMab; ESI QTOF mass spectrometry; Knobs into holes; Quadroma

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; BISPECIFIC ANTIBODY; CATUMAXOMAB; GUANIDINE; IMMUNOGLOBULIN G1; TRIS(2 CARBOXYETHYL)PHOSPHINE; VASCULOTROPIN A; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT PROTEIN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; ELECTROSPRAY; HEAVY CHAIN; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOGENICITY; LIGHT CHAIN; PLASMID; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIZE EXCLUSION CHROMATOGRAPHY; TIME OF FLIGHT MASS SPECTROMETRY; BIOSYNTHESIS; CHEMISTRY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; MASS SPECTROMETRY;

ANTIBODIES, BISPECIFIC; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MASS SPECTROMETRY; RECOMBINANT PROTEINS;

EID: 84964461974     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1111498     Document Type: Article

References (39)

1. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012; 12:12; PMID:22896757
2. Kontermann RE. Dual targeting strategies with bispecific antibodies. Mabs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
3. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j. molimm.2015.01.003
4. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772; http://dx.doi.org/10.1038/305537a0
5. Suresh MR, Cuello AC, Milstein C. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc Natl Acad Sci U S A 1986; 83:7989-93; PMID:2429324; http://dx.doi.org/10.1073/pnas.83.20.7989
6. Moldenhauer G. Bispecific antibodies from hybrid hybridoma. In: Kontermann RE (ed.), Bispecific Antibodies, Springer-Verlag Berlin Heidelberg 2011:29-46
7. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol. 1995; 155:219-25; PMID:7602098
8. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
9. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
10. Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. Mabs 2011; 3:546-57; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
11. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and × restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012; 18:1570-4; PMID:23023498; http://dx.doi.org/10.1038/nm.2942
12. Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012.04.020
13. Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. Mabs 2013; 5:646-54; PMID:23924797; http://dx.doi.org/10.4161/mabs.25632
14. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. Mabs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
15. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx. doi.org/10.1016/S0022-1759(00)00339-2
16. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M1-10.113910
17. Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, Sekimori Y, Orita T, Aso Y, Hattori K, Tsuchiya M. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng Des Sel 2010; 23:667-77; PMID:20576629; http://dx.doi.org/10.1093/protein/gzq034
18. Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H. et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 2015; 290:7535-62; PMID:25583986; http://dx.doi.org/10.1074/jbc.M114.620260
19. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
20. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx. doi.org/10.1073/pnas.1019002108
21. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 2013; 19:6730-40; PMID:24097868; http://dx. doi.org/10.1158/1078-0432.CCR-13-0081
22. Cheung GCM, Barathi VA, Tun BB, Yeo SW, Gan PP, Nyein CL, Regula J, Hartman G. Dual inhibition of angiopoietin-2 and vascular endothelial growth factor-A with Crossmab RG7716 suppressed laser-induced choroidal neovascularization in a non-human primate model. Invest Ophthalmol Vis Sci 2014; 55:1174; http://dx.doi.org/10.1167/iovs.13-11636
23. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
24. Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Meth Enzymol 1986; 121:210-28; PMID:3724461; http://dx.doi. org/10.1016/0076-6879(86)21019-8
25. Smith W, Jarrett AL, Beattie RE, Corvalan JR. Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies. Hybridoma 1992; 11:87-98; PMID:1737643; http://dx.doi.org/10.1089/hyb.1992.-11.87
26. Tada H, Toyoda Y, Iwasa S. Bispecific antibodyproducing hybrid hybridoma and its use in one-step immunoassays for human lymphotoxin. Hybridoma. 1989; 8:73-83; PMID:2647617; http://dx.doi.org/10.1089/hyb.1989.8.73
27. Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, et al. A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors. PLoS One 2013; 8:e54923; PMID:23405099; http://dx.doi. org/10.1371/journal.pone.0054923
28. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9; PMID:9377574
29. In all cases, including Table and Figures, the intended bispecific antibody is underlined
30. De Préval C, Fougereau M. Specific interaction between VH and VL regions of human monoclonal immunoglobulins. J Mol Biol. 1976; 102:657-78; http://dx.doi.org/10.1016/0022-2836(76)90340-5
31. Kranz DM, Voss EW Jr. Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies. Proc Natl Acad Sci U S A 1981; 78:5807-11; PMID:6795637; http://dx.doi.org/10.1073/pnas.78.9.5807
32. Stevenson GT, Mole LE. The specificity of chain interactions among immunoglobulins. Combinations of gamma chains with kappa chains of the same subgroup as in the parent immunoglobulin G. Biochem J 1974; 139:369-74; PMID:4217181; http://dx.doi.org/10.1042/bj1390369
33. De Lau WB, Heije K, Neefjes JJ, Oosterwegel M, Rozemuller E, Bast BJ. Absence of preferential homologous H/L chain association in hybrid hybridomas. J Immunol 1991; 146:906-14; PMID:1899099
34. Hamel PA, Isenman DE, Klein MH, Luedtke R, Dorrington KJ. Structural basis for the preferential association of autologous immunoglobulin subunits: role of the J region of the light chain. Mol Immunol. 1984; 21:277-83; PMID:6427603; http://dx.doi.org/10.1016/0161-5890(84)90098-1
35. Hamel PA, Klein MH, Dorrington KJ. The role of the VL-and VH-segments in the preferential reassociation of immunoglobulin subunits. Mol Immunol 1986; 23:503-10; PMID:3092029; http://dx.doi.org/10.1016/0161-5890(86)90113-6
36. Hamel PA, Klein MH, Smith-Gill SJ, Dorrington KJ. Relative noncovalent association constant between immunoglobulin H and L chains is unrelated to their expression or antigen-binding activity. J Immunol 1987; 139:3012-20; PMID:3117886
37. Brezinschek HP, Foster SJ, Dörner T, Brezinschek RI, Lipsky PE. Pairing of variable heavy and variable kappa chains in individual naive and memory B cells. J Immunol 1998; 160:4762-7; PMID:9590222
38. Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs. 2013; 5:445-70; PMID:23571156; http://dx. doi.org/10.4161/mabs.24218
39. Jayaram N, Bhowmick P, Martin AC. Germline VH/VL pairing in antibodies. Protein Eng Des Sel 2012; 25:523-9; PMID:22802295; http://dx.doi.org/10.1093/protein/gzs043